Savara Inc. (the "Company"), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management team will host 1x1 meetings and participate in ...

Our latest Focus Issue looks at what we’ve learnt over the past decade and what’s next for the field of trained immunity.

The articles in this focus issue discuss progress towards a more complete understanding of memory in the innate immune system, and efforts to exploit "trained immunity" for the development of new ...

First-in-Human Phase 1 data for allogeneic CAR-T cell therapy for NHL to be featured in oral session ...